{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T08:40:02Z","timestamp":1749199202555,"version":"3.41.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100013779","name":"Sabzevar University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Recent developments in targeted radiopharmaceuticals offer promising options for diagnosis and treatment by specifically targeting the overexpressed somatostatin receptors in neuroendocrine tumors (NETs). This study aims to assess the radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of NETs. Four patients were selected for imaging using 177Lu-octreotide or DOTATATE via Single photon emission computed tomography\/Computed tomography (SPECT\/CT). The absorbed doses were calculated employing the Medical Internal Radiation Dose (MIRD) method and S-value tables associated with 177Lu, utilizing the GEANT4 Application for Tomographic Emission (GATE) calculation code. The mean percentage differences in the S-values between the GATE and IDAC2.1 calculation methods were\u00a0\u22120.7 for S (Spleen\u2192Spleen), \u22123.5 for S (Kidneys\u2192Kidneys), and 4.9 for S (Liver\u2192Liver). The mean absorbed doses from the GATE were 0.076, 0.20, 0.29, and 0.47\u00a0mGy\/MBq for the liver, kidneys, spleen, and tumors, respectively. Assessment of the results obtained from the GATE code as a voxel-level dose calculation tool in non-uniform media showed that 177Lu-DOTATATE may provide beneficial therapeutic effects.<\/jats:p>","DOI":"10.1093\/rpd\/ncaf054","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T11:39:10Z","timestamp":1745840350000},"page":"602-611","source":"Crossref","is-referenced-by-count":0,"title":["Radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of neuroendocrine tumors: a hybrid study of patient and simulation"],"prefix":"10.1093","volume":"201","author":[{"given":"Alireza","family":"Seyedabadi","sequence":"first","affiliation":[{"name":"Student Research Committee, Sabzevar University of Medical Sciences , Shohadaye Hasteiee Blvd, Sabzevar, 9617913112 ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pejman","family":"Porouhan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Vasee Hospital, Sabzevar University of Medical Sciences , Shohadaye Hasteiee Blvd, Sabzevar, 9617747431 ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid-Reza","family":"Sadoughi","sequence":"additional","affiliation":[{"name":"Department of Medical Physics and Radiology, Faculty of Medicine, North Khorasan University of Medical Sciences , Dowlat Blvd, Bojnurd, 9414975516 ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruhollah","family":"Ghahramani-Asl","sequence":"additional","affiliation":[{"name":"Department of Medical Physics and Radiological Sciences, Faculty of Paramedicine, Sabzevar University of Medical Sciences , Shohadaye Hasteiee Blvd, Sabzevar, 961791311 ,","place":["Iran"]},{"name":"Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences , Shohadaye Hasteiee Blvd, Sabzevar, 9617913112 ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"volume-title":"Plymouth Meeting","author":"Neuroendocrine and adrenal tumors","key":"2025060604265254600_ref1"},{"author":"Neuroendocrine tumors: introduction","key":"2025060604265254600_ref2"},{"volume-title":"Allscripts EPSi","year":"2024","author":"Warner","key":"2025060604265254600_ref3"},{"key":"2025060604265254600_ref4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA oncology"},{"key":"2025060604265254600_ref5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1196\/annals.1294.025","article-title":"Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center","volume":"1014","author":"Pape","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"2025060604265254600_ref6","doi-asserted-by":"publisher","first-page":"109082","DOI":"10.1016\/j.radphyschem.2020.109082","article-title":"Dosimetric evaluation of several candidate radionuclides used in radionuclide therapy of bone metastases in an upper leg model","volume":"176","author":"Ghahramani-Asl","year":"2020","journal-title":"Radiat Phys Chem"},{"key":"2025060604265254600_ref7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4103\/ijnm.ijnm_6_21","article-title":"Prediction of absorbed dose to normal organs with endocrine tumors for 131I by use of 99mTC single photon emission computed tomography\/computed tomography and Geant4 application for tomographic emission simulation","volume":"36","author":"Asl","year":"2021","journal-title":"Indian Journal of Nuclear Medicine"},{"key":"2025060604265254600_ref8","doi-asserted-by":"publisher","first-page":"e3986","DOI":"10.7759\/cureus.3986","article-title":"Neuroendocrine tumor therapy with Lutetium-177: a literature review","volume":"11","author":"Maqsood","year":"2019","journal-title":"Cureus"},{"key":"2025060604265254600_ref9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40658-024-00658-8","article-title":"A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?","volume":"11","author":"Vergnaud","year":"2024","journal-title":"EJNMMI physics"},{"key":"2025060604265254600_ref10","doi-asserted-by":"publisher","DOI":"10.1118\/1.4892606","article-title":"Comparison of internal dose estimates obtained using organ-level, voxel S value, and Monte Carlo techniques","volume":"41","author":"Grimes","year":"2014","journal-title":"Med Phys"},{"key":"2025060604265254600_ref11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4103\/1450-1147.174700","article-title":"A 3D Monte Carlo method for estimation of patient-specific internal organs absorbed dose for 99mTc-hynic-Tyr3-octreotide imaging","volume":"15","author":"Momennezhad","year":"2016","journal-title":"World journal of nuclear medicine"},{"key":"2025060604265254600_ref12","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1088\/0031-9155\/49\/19\/007","article-title":"GATE: a simulation toolkit for PET and SPECT","volume":"49","author":"Jan","year":"2004","journal-title":"Phys Med Biol"},{"key":"2025060604265254600_ref13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2967\/jnmt.123.265668","article-title":"A review, pat Zanzonico","volume":"52","author":"The MIRD Schema for Radiopharmaceutical Dosimetry","year":"2024","journal-title":"Journal of Nuclear Medicine Technology"},{"key":"2025060604265254600_ref14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry\u2014standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J Nucl Med"},{"key":"2025060604265254600_ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-017-0339-3","article-title":"IDAC-dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms","volume":"7","author":"Andersson","year":"2017","journal-title":"EJNMMI Res"},{"key":"2025060604265254600_ref16","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.2967\/jnumed.111.100123","article-title":"MIRD pam-phlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy","volume":"53","author":"Dewaraja","year":"2012","journal-title":"J Nucl Med"},{"key":"2025060604265254600_ref17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s12149-018-1276-6","article-title":"Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to 177Lu-DOTATATE","volume":"32","author":"Escala Cornejo","year":"2018","journal-title":"Ann Nucl Med"},{"key":"2025060604265254600_ref18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025060604265254600_ref19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12885-020-07710-7","article-title":"Lutetium oxodotreotide (177Lu-DOTATATE) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland","volume":"21","author":"Smith-Palmer","year":"2021","journal-title":"BMC Cancer"},{"key":"2025060604265254600_ref20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2967\/jnumed.114.148437","article-title":"Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"56","author":"Ilan","year":"2015","journal-title":"J Nucl Med"},{"key":"2025060604265254600_ref21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1053\/j.semnuclmed.2009.10.004","article-title":"Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Kwekkeboom","year":"2010","journal-title":"Semin Nucl Med"},{"key":"2025060604265254600_ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-021-01674-9","article-title":"Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-Octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors","volume":"35","author":"Kobayashi","year":"2021","journal-title":"Ann Nucl Med"},{"key":"2025060604265254600_ref23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","article-title":"Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu] Lu-PSMAALB-56 in patients with mCRPC","volume":"48","author":"Kramer","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025060604265254600_ref24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/RLU.0b013e3182814ac1","article-title":"Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE","volume":"38","author":"Gupta","year":"2013","journal-title":"Clin Nucl Med"},{"volume-title":"Recent Results Cancer Res","author":"Schuchardt","key":"2025060604265254600_ref25","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-27994-2_30"},{"key":"2025060604265254600_ref26","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.apradiso.2012.02.029","article-title":"Gamma-ray emission probabilities in the decay of 177mLu","volume":"70","author":"Kondev","year":"2012","journal-title":"Appl Radiat Isot"},{"key":"2025060604265254600_ref27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.22038\/ijn.2019.38470.1607","article-title":"Assessment Efficacy and Complication of the Distance between Phototherapy Lamps and Neonate\u2019s Body Level on Serum Bilirubin Decrease and Phototherapy Complications in Neonatal Hyperbilirubinemia","volume":"10","author":"Zardosht","year":"2019","journal-title":"Iranian Journal of Neonatology"},{"key":"2025060604265254600_ref28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s13246-015-0367-0","article-title":"Monte Carlo and experimental internal radionuclide dosimetry in RANDO head phantom","volume":"38","author":"Ghahraman Asl","year":"2015","journal-title":"Australas Phys Eng Sci Med"},{"key":"2025060604265254600_ref29","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/HP.0000000000000724","article-title":"Evaluation of the Accuracy of Polymer Gels for Determining Electron Dose Distributions in the Presence of Small Heterogeneities","volume":"113","author":"Asl","year":"2017","journal-title":"Health Phys"}],"container-title":["Radiation Protection Dosimetry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rpd\/article-pdf\/201\/8\/602\/63300429\/ncaf054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rpd\/article-pdf\/201\/8\/602\/63300429\/ncaf054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T08:26:59Z","timestamp":1749198419000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rpd\/article\/201\/8\/602\/8141130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,5,23]]},"published-print":{"date-parts":[[2025,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rpd\/ncaf054","relation":{},"ISSN":["0144-8420","1742-3406"],"issn-type":[{"type":"print","value":"0144-8420"},{"type":"electronic","value":"1742-3406"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]}}}